"Why 7 Trillion Won for Aribio? The Best Card for U.S. Market Entry"
Vivian Peng, Head of BD at Fushing Pharmaceuticals, Interview
"AR1001: Strengths as an Oral and Combination Therapy"
"A Strategic Asset to Drive Fushing's Leap Toward Becoming a C-MNC"
"There are many capable Korean companies that are willing to transfer global exclusive licensing rights and have data reliability on par with the United States and Europe. The technology export agreement with Aribio is a prime example that reflects these characteristics of the Korean market," she said.
Vivian Peng, Head of Business Development at Fushing Pharmaceuticals, explained the background of introducing Aribio's dementia drug candidate during an interview with a reporter at the BioChina event held at Seoul Startup Hub M+ in Magok, Gangseo-gu, Seoul on July 9. The oral dementia drug candidate AR1001 is not designed to compete with existing dementia drugs, but rather to be used in combination with them. According to Peng, for Fushing Pharmaceuticals—which aims to become a multinational pharmaceutical company rooted in China—AR1001 is an ideal “first product” for direct entry into the U.S. market.
Vivian Peng, Head of Business Development at Fushing Pharmaceutical, is responding during an interview held on the 9th at Seoul Startup Hub M+ in Magok, Gangseo-gu, Seoul. Photo by Jungyeon Park
View original imageBack in May, Fushing Pharmaceuticals signed a technology export deal with Aribio worth up to 4.7 billion USD (about 7 trillion won) for the global development, approval, and commercialization rights to AR1001. The upfront payment was 60 million USD (about 90 billion won). In addition, through a strategic equity investment of about 42.5 billion won, Fushing Pharmaceuticals became the third largest shareholder of Aribio.
Peng strongly praised the technical completeness of AR1001. AR1001 is an oral PDE5 inhibitor taken once daily. According to Aribio, it is considered a candidate with “disease-modifying” potential, not just slowing symptoms but inhibiting disease progression itself. Peng stated, "So far, the clinical data have shown a low risk of side effects as well as promising efficacy potential. As an oral drug that allows for cost control and combines both safety and efficacy, it holds significant commercial value," she said.
Fushing Pharmaceuticals explained that, based on these data, it selected AR1001 as its first product to advance toward becoming a China-rooted multinational pharmaceutical company (C-MNC). Peng said, "Becoming a C-MNC is the main goal for the next five years, and selecting the right first product for entry into the U.S. market is critical. As with BioNTech's entry into the U.S. market with the COVID-19 vaccine, we needed an asset with good late-stage clinical data and a large indication."
Regarding why Fushing chose a Korean company rather than a U.S. or European company, she pointed to the ease of securing licensing rights. U.S. and European companies tend to tie up global rights first if the data are strong, while Korean companies are more inclined to start with regional collaboration and co-development.
Peng predicted that AR1001 will not be a "competitor" to existing dementia drugs but rather a "complement." Recently commercialized antibody treatments such as Lecanemab and Donanemab specifically target and clear amyloid-beta protein—implicated in Alzheimer's—but require intravenous infusions and pose risks of brain edema and microhemorrhage (ARIA). Since AR1001 is an oral medication and works by a different mechanism of action, it can be used in combination with such antibody therapies, Peng explained.
Fushing Pharmaceuticals is open to additional partnerships with Korean biotech assets, starting with Aribio. Peng said, "Whether it's Korean or global biotech, we consider all attractive assets." She also noted that cooperation with Aribio can expand beyond AR1001, adding, "Our goal is to forge long-term alliances with companies that have platform technologies and independent innovation capabilities."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Fushing Pharmaceuticals is a major Chinese pharmaceutical company listed on the Shanghai and Hong Kong stock exchanges. Last year, it posted revenue of 41.662 billion yuan (about 8 trillion won), with overseas sales of 12.977 billion yuan (about 2.5 trillion won). According to the Chinese Pharmaceutical Industry Information Center under the Ministry of Industry and Information Technology, Fushing Pharmaceuticals ranked sixth last year in the "Top 100 Chinese Pharmaceutical Industry Companies" based on annual revenue.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.